Novo Nordisk A/S (NYSE:NVO) Shares Sold by DGS Capital Management LLC

DGS Capital Management LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,003 shares of the company’s stock after selling 381 shares during the quarter. Novo Nordisk A/S comprises 1.4% of DGS Capital Management LLC’s holdings, making the stock its 10th largest holding. DGS Capital Management LLC’s holdings in Novo Nordisk A/S were worth $5,001,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of NVO. Envestnet Asset Management Inc. increased its holdings in Novo Nordisk A/S by 1.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock worth $607,242,000 after purchasing an additional 58,935 shares in the last quarter. Raymond James & Associates grew its holdings in Novo Nordisk A/S by 1.0% during the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after buying an additional 36,223 shares in the last quarter. Natixis Advisors LLC raised its position in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. Finally, DSM Capital Partners LLC lifted its stake in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NYSE NVO traded down $2.00 during trading hours on Friday, hitting $106.61. The company had a trading volume of 885,839 shares, compared to its average volume of 4,507,520. The firm has a 50 day simple moving average of $110.75 and a 200 day simple moving average of $126.48. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52 week low of $96.53 and a 52 week high of $148.15. The firm has a market capitalization of $478.42 billion, a price-to-earnings ratio of 35.16, a PEG ratio of 1.43 and a beta of 0.40.

Analyst Ratings Changes

NVO has been the subject of several analyst reports. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $150.40.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.